clinical trial · NCT07359820
A Study of Lirafugratinib in Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement
FGFR2 Gene Fusion/RearrangementOther Solid Tumors, AdultLirafugratinib
brief summary
The goal of this clinical trial is to evaluate if lirafugratinib is efficacious and safe to treat adult patients with previously treated, unresectable, locally advanced or metastatic solid tumors (excluding cholangiocarcinoma) harboring FGFR2 fusion or rearrangement. Participants will: * Take lirafugratinib regularly as instructed by their study doctor. * Visit the clinic as instructed for checkups and tests. * Keep a diary recording each time a dose of lirafugratinib is taken.
started
May 1, 2026
primary completion
Sep 1, 2027
completion
Dec 1, 2028
last updated
May 1, 2026
official title
A Phase 2, Open-Label, Single-Arm Study of Lirafugratinib in Patients With Previously Treated, Unresectable, Locally Advanced or Metastatic Solid Tumors (Excluding Cholangiocarcinoma) With FGFR2 Fusion or Rearrangement
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol